Author Torres Urtizberea, Endika |
Abstract Among all the different cancers, pancreatic cancer is considered to have one of the lowest survivability rates. Currently, among the only five approved small drugs in the U.S. by the FDA for the treatment of this cancer two of them target growth factor receptors (GFR), that’s why, the inhibition of these kind of proteins has become of interest. Furthermore, due to drug resistance linked to cross talks between these, the necessity of selective multiple growth factor inhibitors has grown among the medicinal scientists. |
|
Director Estrada Tejedor, Roger |
||
Degree IQS SE - Máster en Química Farmacéutica |
||
Date 2019-12-10
|